Physician profile
Marvin Bernstein
NPI 1508856519
$536.94
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $15.55.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $189.64 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $156.89 | 2019 | |
| Alexion Pharmaceuticals, INC. | $61.81 | 2019 | |
| Opko Pharmaceuticals, LLC | $40.73 | 2019 | |
| Fresenius USA Marketing, INC. | $27.69 | 2019 | |
| Amgen INC. | $26.79 | 2019 | |
| Travere Therapeutics, INC. | $19.70 | 2019 | |
| Genzyme Corporation | $13.69 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.